Photo of Rebecca Chin,  PhD

Rebecca Chin, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 735-2484


rchin1@bidmc.harvard.edu

Rebecca Chin, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Pathology, Harvard Medical School
  • Assistant Professor, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My primary research interest is to dissect the PI 3-K/Akt signaling pathway in cancer progression using biochemical, genomic and bioinformatics approaches. The discovery that the Akt signaling cascade is one of the most frequently mutated pathways in cancer, and the considerable efforts in developing Akt inhibitors as anti-cancer therapeutics, makes this an exciting time for basic and translational research relating to this pathway. A major research focus in my laboratory is the identification of distinct functions of Akt isoforms in different tumor contexts. We aim at discovering novel Akt isoform-specific targets, with an emphasis on their implications in personalized targeted therapy.

Publications

Powered by Harvard Catalyst
  • Chin YM, Yuan X, Balk SP, Toker A. Pten-deficient tumors depend on akt2 for maintenance and survival. 2014. PubMed
  • Toker A, Chin YR. Akt-ing up on SRPK1: oncogene or tumor suppressor? Mol Cell 2014; 54:329-30. PubMed
  • Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res 2014; 74:964-73. PubMed
  • Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE. RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res 2012. PubMed
  • Inuzuka H, Gao D, Finley LW, Yang W, Wan L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, Wang Z, Gygi SP, Nakayama K, Teruya-Feldstein J, Toker A, Haigis MC, Pandolfi PP, Wei W. Acetylation-dependent regulation of Skp2 function. Cell 2012; 150:179-93. PubMed
  • Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW, Wei W. mTOR drives its own activation via SCF(硫TrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 2011; 44:290-303. PubMed
  • Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT Promotes Carcinoma Invasive Migration Through Glypican-6. Biochem J 2011. PubMed
  • Chin YR, Toker A. Akt2 regulates expression of the actin-bundling protein palladin. FEBS Lett 2010; 584:4769-74. PubMed
  • Chin YR, Toker A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell 2010; 38:333-44. PubMed
  • Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009; 69:6299-306. PubMed
  • Gao D,Inuzuka H,Tseng A,Chin RY,Toker A,Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol 2009; 11:397-408. PubMed
  • Chin YR,Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2008; 21:470-6. PubMed
  • Yoeli-Lerner M,Chin YR,Hansen CK,Toker A. Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 2009; 7:425-32. PubMed
  • Chin YR, Horwitz MS. Adenovirus RID complex enhances degradation of internalized tumour necrosis factor receptor 1 without affecting its rate of endocytosis. J Gen Virol 2006; 87:3161-7. PubMed
  • Chin YR, Horwitz MS. Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex. J Virol 2005; 79:13606-17. PubMed
  • Fessler SP, Chin YR, Horwitz MS. Inhibition of tumor necrosis factor (TNF) signal transduction by the adenovirus group C RID complex involves downregulation of surface levels of TNF receptor 1. J Virol 2004; 78:13113-21. PubMed
  • Zho S, Chiang D, Chin R, Kestell P, Paxton JW. High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 767:19-26. PubMed
  • Chin YR, Toker A. Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr 2011; 5:211-4. PubMed
Hide